Network meta-analysis of 4 trials in men with metastatic hormone-sensitive prostate cancer: darolutamide plus ADT delayed FACT-P quality-of-life deterioration vs ADT (HR 0.76) and apalutamide plus ADT (HR 0.74), with no evidence of difference vs abiraterone or enzalutamide.
Meta-analysisn = 4 trials
Shore et al. Health-related Quality of Life With ARPIs in mHSPC: Insights From a Network Meta-analysis